{"status": "ok", "totalResults": 1, "articles": [{"source": {"id": null, "name": "Astrazeneca.com"}, "author": null, "title": "Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial - AstraZeneca", "description": "", "url": "https://www.astrazeneca.com/media-centre/press-releases/2023/dato-dxd-improved-pfs-in-breast-cancer.html", "urlToImage": "", "publishedAt": "2023-09-22T01:30:00Z", "content": "Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the p\u2026 [+9913 chars]"}]}